Brokerages Set CeriBell (NASDAQ:CBLL) Price Target at $32.60

CeriBell (NASDAQ:CBLL) has earned an average rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $32.50.

A number of brokerages recently commented on CBLL. TD Cowen boosted their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Canaccord Genuity Group restated a “buy” rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Finally, LADENBURG THALM/SH SH started coverage on shares of CeriBell in a report on Friday. They set a “buy” rating and a $32.00 price objective for the company.

CeriBell Stock Down 1.5 %

Shares of CBLL stock opened at $18.44 on Friday. CeriBell has a fifty-two week low of $17.67 and a fifty-two week high of $32.75. The business has a 50 day simple moving average of $21.95.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. On average, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently made changes to their positions in CBLL. Legal & General Group Plc purchased a new position in CeriBell during the fourth quarter worth about $32,000. Summit Investment Advisors Inc. bought a new position in shares of CeriBell during the 4th quarter worth approximately $33,000. Tower Research Capital LLC TRC purchased a new position in shares of CeriBell in the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets bought a new position in shares of CeriBell in the fourth quarter valued at approximately $43,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the fourth quarter valued at approximately $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.